<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923597</url>
  </required_header>
  <id_info>
    <org_study_id>Fapesp-2013</org_study_id>
    <nct_id>NCT01923597</nct_id>
  </id_info>
  <brief_title>Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.</brief_title>
  <official_title>A Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Green Tea on Albuminuria in Patients With Diabetic Nephropathy and Use of Maximum Dose of ACE-I and / or Angiotensin II Receptor Blocker.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effect of green tea
      (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical, prospective, randomized, double-blind, placebo-controlled, with analysis by
      intention to treat.

      50 individuals will be selected with a diagnosis of diabetes / hypertension and has been
      followed in Diabetic Nephropathy Clinic of the Faculty of Medical Sciences, University of
      Campinas (UNICAMP). Participants are divided into 02 groups: 1) 25 patients treated with
      maximum dose of ACE-I and / or angiotensin II receptor blocker (ARBs) + Placebo (absence of
      epigallocatechin gallate) and 2) treated 25 patients with maximum dose of ACE-I and / or ARBs
      + green tea (epigallocatechin gallate).

      The patients will receive four capsules Polyphenol E - epigallocatechin gallate (Polyphenon
      Pharma, NY) per day, corresponding to 800 mg of epigallocatechin gallate (EGCG), or placebo
      (no epigallocatechin gallate) for 3 months. Patients will not be aware of the treatment they
      are receiving. The subjects will be allocated for the treatment or placebo, stratified by
      sex. To avoid the influence of researchers, the randomization list will be generated and
      maintained by trained personnel in a different location from the study. Before treatment and
      immediately after 3 months of treatment will be obtained in the primary outcome measures
      (albuminuria) and secondary (plasma metabolites of flavonoids, level of urinary
      F2-isoprostane and 8-hydroxydeoxyguanosine). In these same times will be obtained: blood
      biochemistry (glucose, glycosylated hemoglobin, urea, creatinine, sodium, potassium, blood
      count, calcium, phosphorus, cholesterol, LDL, HDL, triglycerides, uric acid), 3 samples of
      first morning urine to determine albuminuria, glomerular filtration rate (GFR), blood
      pressure measurement of 24 h, physical examination, weight, blood pressure and heart rate.
      Adherence to the study will be evaluated by weekly phone and the expected increase in plasma
      of flavonoids using the green tea (epigallocatechin gallate). The antihypertensive drug may
      be adjusted to obtain the desired pressure (&lt;130/80 mmHg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Mean of 3 urinary albumin to creatinine ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on oxidative stress in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Urinary levels of F2-isoprostane and 8-hydroxydeoxyguanosine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on blood glucose control in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of tretatment</time_frame>
    <description>Glycemia and glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on blood pressure in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>24 h blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Plasma levels of HDL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on plasma metabolites of flavonoids in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Plasma levels of epigallocatechin gallate and epicatechin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Plasma levels of LDL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Plasma levels of triglycerides.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.</measure>
    <time_frame>After 3 months of treatment</time_frame>
    <description>Estimated by Modification of Diet in Renal Disease (MDRD) formula.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Green tea extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (celulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive four capsules of placebo (celulose) daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Green tea extract</intervention_name>
    <description>200mg/capsule Administered orally 4 capsules per day For 3 months</description>
    <arm_group_label>Green tea extract</arm_group_label>
    <arm_group_label>Placebo (celulose)</arm_group_label>
    <other_name>Epigallocatechin gallate</other_name>
    <other_name>Polyphenol e</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or more

          -  prior diagnosis of diabetes mellitus (DM)

          -  persistent micro-or macroalbuminuria (urinary albumin excretion&gt; 30 mg / g creatinine
             (AUC) in 3 consecutive measurements on different days)

          -  glycated hemoglobin &lt;10%

          -  maximum dose of ACE-I and / or ARBs.

        Exclusion Criteria:

          -  diagnosis of autoimmune diseases, HIV, hepatitis, cancer, inflammatory disease

          -  pregnant or lactating patients

          -  glomerular filtration rate (GFR) &lt;30 ml/min/1, 73m2 (estimated by the MDRD and the
             Cockcroft-Gault formula)

          -  presence of kidney disease unrelated to diabetes

          -  chronic urinary tract infection

          -  diagnosis of congestive heart failure (CHF) New York Heart Association (NYHA) class
             III or IV

          -  recent history (&lt;6 months) unstable angina, myocardial infarction, stroke, coronary
             intervention

          -  history of alcohol and / or drugs

          -  mental incapacity to understand the informed consent

          -  intolerance to green tea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos√© B. Lopes de Faria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>S√£o Paulo</state>
        <zip>13084-971</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.nature.com/articles/srep28282</url>
    <description>Results</description>
  </link>
  <reference>
    <citation>Faria AM, Papadimitriou A, Silva KC, Lopes de Faria JM, Lopes de Faria JB. Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes. 2012 Jul;61(7):1838-47. doi: 10.2337/db11-1241. Epub 2012 May 14.</citation>
    <PMID>22586583</PMID>
  </reference>
  <reference>
    <citation>Ribaldo PD, Souza DS, Biswas SK, Block K, Lopes de Faria JM, Lopes de Faria JB. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J Nutr. 2009 Jan;139(1):96-100. doi: 10.3945/jn.108.095018. Epub 2008 Dec 3.</citation>
    <PMID>19056645</PMID>
  </reference>
  <results_reference>
    <citation>Borges CM, Papadimitriou A, Duarte DA, Lopes de Faria JM, Lopes de Faria JB. The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial. Sci Rep. 2016 Jun 20;6:28282. doi: 10.1038/srep28282.</citation>
    <PMID>27320846</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Cynthia de Moura Borges</investigator_full_name>
    <investigator_title>master's student</investigator_title>
  </responsible_party>
  <keyword>Proteinuria</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Epigallocatechin gallate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

